Publication: Smoking & risk of advanced liver fibrosis among patients with primary biliary cholangitis: A systematic review & meta-analysis
Issued Date
2021-12-01
Resource Type
ISSN
09715916
Other identifier(s)
2-s2.0-85131701051
Rights
Mahidol University
Rights Holder(s)
SCOPUS
Bibliographic Citation
Indian Journal of Medical Research. Vol.154, No.6 (2021), 806-812
Suggested Citation
Karn Wijarnpreecha, Monia Werlang, Panadeekarn Panjawatanan, Surakit Pungpapong, Frank Lukens, Denise Harnois, Patompong Ungprasert Smoking & risk of advanced liver fibrosis among patients with primary biliary cholangitis: A systematic review & meta-analysis. Indian Journal of Medical Research. Vol.154, No.6 (2021), 806-812. doi:10.4103/ijmr.IJMR_639_19 Retrieved from: https://repository.li.mahidol.ac.th/handle/123456789/75888
Research Projects
Organizational Units
Authors
Journal Issue
Thesis
Title
Smoking & risk of advanced liver fibrosis among patients with primary biliary cholangitis: A systematic review & meta-analysis
Other Contributor(s)
Abstract
Background & objectives: Studies have suggested that smoking may accelerate the progression of fibrosis among patients with primary biliary cholangitis (PBC), although the data are limited. The current review was undertaken with the aim to comprehensively analyze this possible association by identifying all relevant studies and summarizing their results. Methods: A comprehensive literature review on MEDLINE and EMBASE databases was performed from inception through February 2019 to identify all relevant studies. Eligible studies included cross-sectional studies that recruited patients with PBC and collected data on the smoking status and presence or absence of advanced liver fibrosis for each participant. Odds ratios (OR) with 95 per cent confidence intervals (CI) was desirable for inclusion or sufficient raw data to calculate the same for this association. Adjusted point estimates from each study were extracted and combined together using the generic inverse variance method of DerSimonian and Laird. I 2 statistic, which quantifies the proportion of total variation across studies was used to determine the between-study heterogeneity. Results: Three cross-sectional studies with 544 participants were included. The pooled analysis found a significantly increased risk of advanced liver fibrosis among patients with PBC who were ever-smokers compared to those who were nonsmokers with the pooled OR of 3.00 (95% CI, 1.18-7.65). Statistical heterogeneity was high with I 2 of 89 per cent. Interpretation & conclusions: This meta-analysis found that smoking is associated with a significantly higher risk of advanced liver fibrosis among patients with PBC. Further prospective studies are still required to determine whether this association is causal.